NHL: Charlie Coyle is Bruins’ latest addition to COVID protocols

Date:

Share post:


Boston Bruins forward Charlie Coyle was added to the NHL’s COVID-19 health and safety protocols Sunday.

The organization has been hit particularly hard by the virus this month. The Bruins have not played since Dec. 16, with at least nine players and two club staff in the protocols as of Dec. 18.

The NHL extended its previously scheduled holiday break to six days as COVID spread around the league, and it will resume games no sooner than Tuesday. The Bruins’ next game is at the Ottawa Senators on Wednesday, but it remains to be seen whether they will have enough healthy players to dress for the game.

Bruins players who were in COVID protocols when the pause went into effect included top scorer Brad Marchand, captain Patrice Bergeron and goalie Jeremy Swayman. The team was also without coach Bruce Cassidy for a period of time due to him testing positive.

Coyle, 29, has tallied seven goals and seven assists in 26 games this season for Boston. In a 10-year career split between the Minnesota Wild (2012-2019) and the Bruins, Coyle has amassed 315 points (122 goals, 193 assists) over 647 games.

–Field Level Media

spot_img

Related articles

NHL: F Marco Rossi signs 3-year, $15M deal with Wild

Restricted free-agent forward Marco Rossi signed a three-year, $15 million contract with the Minnesota Wild on Friday. Rossi, 23,...

NHL: Report: Verdict in Hockey Canada sexual-assault case won’t be appealed

The government will not appeal the verdict in the case of the five pro hockey players who were...

NHL: Mammoth G Connor Ingram cleared to return to NHL

The player assistance program cleared Utah Mammoth goaltender Connor Ingram to return to the league on Thursday. Ingram, 28,...

NHL: Avalanche sign F Victor Olofsson to 1-year contract

The Colorado Avalanche signed free agent forward Victor Olofsson to a one-year contract on Wednesday. Financial terms were not...

FREE

Get the most important breaking news and analyses for Free.

Thank you for subscribing

Something went wrong.